newsfilter
← Latest News
Business Wire·

Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights

EQ

$33.3 million cash balance at the end of Q2 2024, representing a $1.0 million increase from the end of Q1 2024 Triggered Ono option exercise period to acquire Equillium's rights to itolizumab, decision expected before